Credit Suisse’s Treace Medical Concepts TMCI Stock Holding History

Credit Suisse’s Portfolio TMCI Stock Details TMCI Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q1	$765K	Buy	58,631 +240	+0.4%	+$3.2K	﹤0.01%	2426
2023 Q4	$744K	Buy	58,391 +8,808	+18%	+$89K	﹤0.01%	2530
2023 Q3	$650K	Buy	49,583 +1,662	+3%	+$30.4K	﹤0.01%	2542
2023 Q2	$1.23M	Buy	47,921 +28,498	+147%	+$736K	﹤0.01%	2248
2023 Q1	$489K	Buy	19,423 +2,131	+12%	+$50K	﹤0.01%	2762
2022 Q4	$398K	Buy	17,292 +4,071	+31%	+$93.7K	﹤0.01%	2910
2022 Q3	$291K	Buy	13,221 +161	+1%	+$3.12K	﹤0.01%	3098
2022 Q2	$187K	Buy	13,060 +2,524	+24%	+$42.5K	﹤0.01%	3357
2022 Q1	$199K	Buy	+10,536	New	+$205K	﹤0.01%	3373

Other funds holding TMCI

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return

William Blair Investment Management Chicago, Illinois $30.3B AUM 33.75% 1-Year Est. Return

Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

CIBC Private Wealth Group Atlanta, Georgia $59.2B AUM 20.62% 1-Year Est. Return

Emerald Advisers Leola, Pennsylvania $3.16B AUM 109.58% 1-Year Est. Return

TCM

TimesSquare Capital Management New York $5.89B AUM 28.74% 1-Year Est. Return

Credit Suisse's TMCI Position: Q1 2024 in Review

Credit Suisse increased its Treace Medical Concepts (TMCI) stake by 0.41% in Q1 2024, buying an estimated $3.2K and bringing the position to 58,631 shares worth $765K. The position accounts for ﹤0.01% of the portfolio, ranked #2426.

Credit Suisse first reported a position in TMCI in Q1 2022 and has held it in 9 quarters since. The position peaked at $1.23M in Q2 2023. 132 funds tracked by Wall St. Rank hold TMCI as of Q1 2024.

Credit Suisse held 58,631 shares of Treace Medical Concepts worth $765K as of Q1 2024.
Credit Suisse bought 240 Treace Medical Concepts shares in Q1 2024, an estimated $3.2K.
Treace Medical Concepts made up ﹤0.01% of Credit Suisse's portfolio in Q1 2024, its #2426 holding.
Credit Suisse first reported a position in Treace Medical Concepts in Q1 2022 and has held it in 9 quarters since.
Credit Suisse's Treace Medical Concepts position peaked at $1.23M in Q2 2023.
132 funds tracked by Wall St. Rank held Treace Medical Concepts as of Q1 2024.

Based on Credit Suisse's 13F filing for Q1 2024, filed 10 May 2024.